Rhythm Pharmaceuticals, Inc. (RYTM)
| Market Cap | 2.35B |
| Revenue (ttm) | 77.43M |
| Net Income (ttm) | -184.68M |
| Shares Out | 60.14M |
| EPS (ttm) | -3.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 361,220 |
| Open | 38.31 |
| Previous Close | 38.01 |
| Day's Range | 37.76 - 39.42 |
| 52-Week Range | 15.50 - 52.57 |
| Beta | 1.93 |
| Analysts | Strong Buy |
| Price Target | 47.20 (+21.0%) |
| Earnings Date | May 7, 2024 |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de... [Read more]
Financial Performance
In 2023, RYTM's revenue was $77.43 million, an increase of 227.56% compared to the previous year's $23.64 million. Losses were -$184.68 million, 1.97% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price forecast is $47.2, which is an increase of 21.00% from the latest price.
News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families li...
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 -- -- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into ...
Hennion & Walsh's Kevin Mahn on his top stock picks: CRWD, MSFT, LLY, RYTM
Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'Squawk Box' to discuss the latest market trends, why he believes AI isn't the only game in town for the markets, and more.
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical...
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families li...
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
-- Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024 -- -- Significant unmet need with 5,000 ...
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
-- Fourth quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothal...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Company to participate in fireside chats at Guggenheim's 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5 Company to participate in fireside cha...
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
-- LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation -- -- Rhythm to advance LB54640 in two Phase 2 clinical trials --
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
-- Phase 3 hypothalamic obesity top-line data expected in 1H2025 -- -- Positive reimbursement decision achieved for IMCIVREE ® (setmelanotide) to treat patients with Bardet-Biedl syndrome and POMC/LEP...
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
-- More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases -- -- Approximately 150 healthcare professionals from...
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
-- Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
-- Third quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $22.5 million -- -- More than 100 international patients on reimbursed IMCIVREE therapy --
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
-- CADTH recommends reimbursement for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS) -- -- Recommendation based on demons...
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families liv...
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment -- -- Three of 11 pediatric patients with hypothalamic obesity achieved normal ...
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society's Annual Meeting at ObesityWeek ®
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families liv...
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families li...
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families li...
Rhythm Pharmaceuticals Announces Update to September Conference Participation
BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families li...
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
Specific coding expected to improve disease awareness, understanding and diagnosis and may enhance access to therapies for patients with BBS Specific coding expected to improve disease awareness, unde...
Rhythm Pharmaceuticals to Present at Investor Conferences in September
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families liv...
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
-- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE ® (setmelanotide) -- -- Strong U.S. commercial progress continues with more than 125 new prescriptions for Bardet-Bied...
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
Results of The CAREgiver Burden in BBS (CARE-BBS) study show multifaceted burden of hyperphagia Results of The CAREgiver Burden in BBS (CARE-BBS) study show multifaceted burden of hyperphagia
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
BOSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families liv...